Antara Capital LP Terns Pharmaceuticals, Inc. Transaction History

Antara Capital LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.5 - $3.0 $300,351 - $600,702	-200,234 Reduced 18.63%	874,600 $2.17 Million
Q1 2022 May 16, 2022	BUY	$2.83 - $6.7 $353,750 - $837,500	125,000 Added 13.16%	1,074,834 $3.19 Million
Q4 2021 Feb 14, 2022	BUY	$5.65 - $10.73 $988,750 - $1.88 Million	175,000 Added 22.59%	949,834 $6.72 Million
Q3 2021 Nov 15, 2021	SELL	$7.22 - $13.46 $7,942 - $14,806	-1,100 Reduced 0.14%	774,834 $8.07 Million
Q2 2021 Aug 16, 2021	BUY	$12.26 - $22.0 $295,723 - $530,662	24,121 Added 3.21%	775,934 $9.51 Million
Q1 2021 May 17, 2021	BUY	$17.13 - $27.25 $12.9 Million - $20.5 Million	751,813 New	751,813 $16.3 Million

167

78.3M

580K

454K

Ticker TERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,613,800
Market Cap $224M
Description
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...

Get notified when there are updates to the investment portfolio of Antara Capital LP, based on Form 13F filings with the SEC.

Stay updated on Antara Capital LP with notifications on news.